Photo from wikipedia
Current UK standard of care in frontline advanced stage (III or IV) symptomatic follicular lymphoma (FL) is immuno-chemotherapy with anti-CD20 monoclonal antibodies (mAbs) rituximab (R) or obinutuzumab (O), in combination… Click to show full abstract
Current UK standard of care in frontline advanced stage (III or IV) symptomatic follicular lymphoma (FL) is immuno-chemotherapy with anti-CD20 monoclonal antibodies (mAbs) rituximab (R) or obinutuzumab (O), in combination with cyclophosphamide, vincristine and prednisolone (CVP) or cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP), or bendamustine (B)1 . Maintenance R or O are commonly offered to patients who achieved an objective response to induction1,2 .
Keywords:
efficacy infection;
immuno chemotherapy;
follicular lymphoma
Journal Title: European Journal of Haematology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: European Journal of Haematology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!